Page 38 - Sun Pharma

Sun Pharma medical representatives to go on strike

The strike is also against company's decision to have a uniform structure for paid leave for employees

Sun Pharma to start 14 brand transfers from Novartis

Mitsubishi Tanabe Pharma Corporation will market and distribute all the 14 brands

Sun Pharma inks distribution alliance with Mitsubishi Tanabe

Sun Pharma forayed into Japanese prescription market by acquiring 14 brands from Novartis for $293 million

FDA warns former Sun Pharma US drug factory over quality concerns

The company has been pulled up by USFDA for using contaminated raw materials

Sun Pharma Q1 net zooms over 3-fold at Rs 2,034 cr on strong US sales

Overall consolidated revenue grew 23% to Rs 8,007 cr

Sun Pharma: Guidance overhang despite good Q1 show

Approvals for US launches and clearance of Halol plant key for Sun Pharma's earning upgrades

Sun Pharma Q1 net zooms over 3-fold to Rs 2,034 crore

Company's consolidated total income from operations rose to Rs 8,242.99 crore for the first quarter of the current fiscal

Sun Pharma to launch diabetes tablet in US

Tablets may have an annual sales of around $1.2 billion in the country

Sun Pharma, Almirall enter pact for psoriasis novel biologic

Sun Pharma to receive $50 mn initially, apart from development & regulatory milestone payments, royalties on net sales

Sun Pharmaceutical gains on pact with Almirall for Psoriasis drug

Under terms of the license agreement, Almirall will pay Sun Pharma an initial upfront payment of US $50 million,

Sun Pharma in $50 million deal with Spanish firm Almirall

According to Sun Pharma, Almirall will be able to lead European studies, and participate in larger Global clinical studies for psoriasis indication subject to the terms of the Sun Pharma - Merck agreements

Sun, Glenmark, Aurobindo get USFDA nod for cholesterol drug Crestor

Crestor tablets had posted annual sales of around $6.78 billion in the 12 months ended May 2016

SPARC and Sun Pharma ink licensing pact for epilepsy drug

Shares of SPARC were trading 5.11% at Rs 367.50 apiece on BSE

Sun Pharma Advanced surges on licensing pact with Sun Pharma

SPARC was surged 7% to Rs 375, while Sun Pharma was up 1% at Rs 779 on the BSE.

Sun Pharma introduces anti-cancer product in Europe

Over the next few months, Sun Pharma will launch Gemcitabine InfuSMART across the Netherlands, the UK, Spain, Germany, Italy and France

Sun Pharma trades firm after board approves buyback of shares

The stock was trading flat at Rs 754 on the BSE, as compared to 3.5% fall in the S&P BSE Sensex.

Sun announces share buyback

On a year-on-year basis, Sun Pharma's stock is down 13.7%

Sun Pharma buyback offer a no-show

Given the offer size, it is hardly a blip on the screen

Sun Pharma bets on new products to boost US skincare products growth

Company has high hopes for tildrakizumab, an experimental psoriasis drug that recently completed late-stage trials

Sun Pharma gains ahead of board meet to mull share buyback proposal

The stock was up 2% at Rs 757 on the BSE.